ClinicalTrials.gg
RecruitingNCT07405606Updated Oct 26, 2026

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

A Phase 2 interventional study of Psilocybin 25 mg and Placebo in Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD), sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Centre for Addiction and Mental Health · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing psilocybin in Depressive Disorder, Major — 11 open to participants now, 16 under way, 4 of them phase 3. Psilocybin · Depressive Disorder, Major.

Planned enrollment
17th of 31
30 · median 35
Started
2026
with 4 others
Phase 2
25 of 31
8 open now
Primary completion
2028-03
later than 8 of 15 live
Registered
26th of 31
by date
Lead sponsor
1 of 31
Centre for Addiction and Mental Health

Among the 31 studies testing psilocybin in Depressive Disorder, Major, this one is the 17th largest by planned enrollment, is one of 5 that started in 2026, is one of 25 in phase 2, reaches primary completion later than 8 of the 15 other live ones, and was the 26th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

11 of the 31 studies testing psilocybin in Depressive Disorder, Major are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing psilocybin in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). The main question it aims to answer is:

- What is the feasibility and safety of administering PAT in adults with MDD-AUD by evaluating recruitment, retention, tolerability, and safety?

Researchers will compare the psilocybin (25 mg) and placebo groups to see if there are any significant differences in frequency of dropouts or serious adverse events.

Participants will:

  • be randomized to receive either psilocybin (25 mg) or placebo
  • visit the site (in-person and remotely) for a total of 14 times to complete study tasks
  • receive psilocybin-assisted therapy (PAT) at five various timepoints
03

Conditions studied

  • Major Depressive Disorder (MDD)
  • Alcohol Use Disorder (AUD)

Keywords

  • depression
  • psilocybin
  • alcohol use disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between the ages of 18-65
  • Must be deemed to have capacity to provide ;
  • Ability to read and communicate in English, such that their literacy and comprehension is sufficient for understanding the consent form and study questionnaires, as evaluated by study staff obtaining consent;
  • Stated willingness to comply with all study procedures;
  • Be deemed in health compatible with the study procedures according to study physician;
  • Ability to take oral medication and be willing to adhere to the PAT regimen;
  • Individuals who are capable of becoming pregnant: use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation;
  • Fulfil (5th Edition) (DSM-5) criteria for a primary diagnosis of current single or recurrent episodes of MDD of at least moderate severity but without psychotic features and a comorbid AUD diagnosis (moderate or severe) using the SCID-5;
  • A score of at least 14 on the Hamilton Depression Rating Scale for Depression (HAMD);
  • Participants should not be interested in initiating standard pharmacotherapies for MDD or AUD. The need to start/resume standard pharmacotherapies will be reassessed at Week 6.
  • Individuals who are willing to and tapered off current antidepressant or IMAOs, antipsychotic and anti-alcohol/anti-craving medications for a minimum of 2-weeks (or more depending on the medication) prior to Baseline (V2) and for the duration of the study and whose physician confirms that it is safe for them to do so;
  • Individuals who are willing to and have tapered off current inhibitors of 5'-diphospho-glucuronosyltransferase (UGT)1A9 and 1A10, aldehyde dehydrogenase inhibitors (ALDHs) and alcohol dehydrogenase inhibitors (ADHs) for a minimum of 2-weeks (or more depending on the medication) prior to Baseline (V2) and for the duration of the study and whose physician confirms that it is safe for them to do so;
  • Agreement to adhere to Lifestyle Considerations (section 4.5) throughout study duration.

Exclusion criteria

Exclusion Criteria:

  • Pregnant as assessed by a urine pregnancy test at Screening (V1) and Baseline (V2) or individual's that intend to become pregnant during the study or are breastfeeding;
  • Presence of a relative or absolute to psilocybin, including a drug allergy, recent stroke history, uncontrolled hypertension (over 160/100 mmHG), low or labile blood pressure, recent myocardial infarction, cardiac arrhythmic, severe coronary artery disease, or moderate to severe renal or hepatic impairment.
  • Diagnosis of cirrhosis, or ALT elevations > 3x ; significant abnormal liver function that would preclude administration of psilocybin based on the judgement of the QI (assessed notably by , albumin, alkaline phosphatase, GGT, and functions)
  • Any lifetime diagnosis of a schizophrenia-spectrum disorder; obsessive-compulsive disorder, psychotic disorder (unless substance induced or due to a medical condition), bipolar I or II disorder, paranoid personality disorder, borderline personality disorder, or neurocognitive disorder as determined by medical history and the SCID-5 clinical interview;
  • Any first-degree relative with a diagnosis of schizophrenia-spectrum disorder; psychotic disorder (unless substance-induced or due to a medical condition); or bipolar I or II disorder as determined by the family medical history form and discussions with the participant;
  • Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) score > 9, or any other indication that the participant may experience medically complicated withdrawal from alcohol, such as a score of ≥4 in the Prediction of Alcohol Withdrawal Severity Scale.
  • Use benzodiazepines (with the exception of use of up to 2mg of lorazepam equivalent per day for insomnia and anxiety if it is not taken within 12 hours before the psilocybin dose (Week 2).
  • Have a DSM-5 diagnosis of substance use disorder (excluding alcohol, cannabis, tobacco and caffeine) within the preceding 6 months;
  • Presence of baseline prolonged (more than 0.45 seconds for males and 0.47 seconds for females) or Torsade de Pointes as measured by the or a history of long QTc syndrome or related risk factors;
  • Use of aldehyde dehydrogenase (ALDH) inhibitors and UDG modulators;
  • Use of hallucinogens in the past 5 years; or total hallucinogen use ≥10 times)
  • Current suicidality risk as indicated during the conduct of the Columbia Suicide Severity Rating Scale (C-SSRS) with concurrence after a study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes")
  • Any other physical illness including chronic infectious diseases or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study.
  • Participants that are responding to anti-alcohol or anti-craving medications
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Psilocybin (25 mg)

    Participant is administered one oral capsule (25 mg psilocybin) with water.

    Drug: Psilocybin 25 mg

  • Placebo comparator
    Placebo

    Participant is administered one oral capsule (0 mg psilocybin) with water.

    Drug: Placebo

Interventions

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will orally consume Psilocybin (25 mg) with water.

  • DrugPlacebo

    Participants will orally consume placebo matching the intervention with water.

06

What researchers measure

Primary outcomes

  1. Adherence

    Although all administration of psilocybin will be administered by qualified staff, the investigators will measure adherence through visit compliance (i.e., missed visits).

    Time frame: Week 2 (Visit 4)

  2. Montgomery-Asberg Depression Rating Scale (MADRS)

    Used to assess changes in depressive symptoms on a 10-item scale with each item rated on a scale of 0-6. Higher scores indicate greater severity of symptoms.

    Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

  3. Hamilton Depression Rating Scale (HAMD-17)

    Used to assess changes in depressive symptoms using 3-point (0-2) or 5-point (0-4) Likert scales. Higher scores indicate greater severity of symptoms.

    Time frame: 4-week post dose; week 26.

  4. Quick Inventory of Depressive Symptomatology - Self Report (QUIDS-SR)

    Used to assess changes in depressive symptoms with a minimum score of 0 to a maximum score of 27.

    Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

  5. Alcohol Timeline Followback (TLFB)

    To monitor alcohol consumption, heavy drinking days, drinks per day, drinks per drinking day, percent very heavy drinking days, percent participants with no heavy drinking days, and abstinent percent will be measured.

    Time frame: Baseline; week 2 (visit 3); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

  6. Clinical Institute Withdrawal Assessment (CIWA)

    Used to assess alcohol withdrawal symptoms. Scores range from 0 to 67 with higher scores indicating greater severity of withdrawal symptoms.

    Time frame: Baseline; week 2 (visit 3); week 2 (visit 4); 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

  7. Prediction of Alcohol Withdrawal Severity Scale (PAWSS)

    Used to assess risk of alcohol withdrawal symptoms using a 10-item scale with the total score ranging from 0 to 10. Higher scores indicate greater risk of withdrawal symptoms.

    Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

  8. Penn Alcohol Craving Scale (PACS)

    Used to assess history, frequency, and consequences of alcohol use. Scores range from 0 to 30 with higher scores indicating greater craving.

    Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

  9. Addiction Severity Index (ASI)

    Used to assess history, frequency, and consequences of alcohol use

    Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post dose; 4-week post dose; week 10; week 14; week 18; week 22; week 26.

Secondary outcomes

  1. 5 Dimensional Altered States of Consciousness (5-DASC)

    Used to assess subjective effects of psilocybin. Minimum value of 0 to maximum value of 100, with higher scores representing greater reports of alterations to normal waking consciousness.

    Time frame: Week 2 (visit 4).

  2. Psychological Insight Questionnaire (PIQ)

    Used to assess subjective effects of psilocybin. Contains 23 items rated on a 5-point Likert scale. Higher scores generally indicate greater intensity of psychological insight.

    Time frame: Week 2 (visit 4).

  3. Mystical Experience Questionnaire (MEQ)

    Used to assess subjective effects of psilocybin. Contains 30 items rated on a 5-point Likert scale. Higher scores indicate greater mystical experience.

    Time frame: Week 2 (visit 4).

  4. Challenging Experience Questionnaire (CEQ)

    Used to assess subjective effects of psilocybin. Contains 26 items rated on a 5-point Likert scale. Higher scores generally indicate more challenging experience or distress.

    Time frame: Week 2 (visit 4).

  5. General Anxiety Disorder-7th edition (GAD-7)

    Used to assess anxiety-related symptoms. Scores range from 0 to 21 with higher scores indicating greater severity of anxiety symptoms.

    Time frame: Baseline; week 26.

  6. State Trait Anxiety Index (STAI)

    Used to assess anxiety-related symptoms. Scores range from 20 to 80 with higher scores indicating greater severity of anxiety symptoms.

    Time frame: Baseline; week 26.

  7. World Health Organization Quality of Life Questionnaire Brief Version (WHOQOL-BREF)

    Used to assess overall quality of life. Scores range from 0 to 100 with higher scores indicating greater quality of life.

    Time frame: Baseline; week 26.

  8. Big Five Inventory (BFI)

    Used to assess personality. Contains 44 items with each item rated on a five-point Likert scale from 1 (disagree a lot) to 5 (agree a lot). Higher scores in each trait indicates stronger association to the trait.

    Time frame: Baseline; week 26.

  9. Pittsburgh Sleep Quality Index (PSQI)

    Used to assess quality of sleep. Score ranges from 0 to 21 with higher scores indicating greater disturbance to sleep.

    Time frame: Baseline; week 26.

  10. Acceptance & Action Questionnaire II (AAQ-II)

    Used to assess psychological flexibility. There are 7-items each rated on a 7-point Likert scale. Higher scores indicate greater psychological inflexibility.

    Time frame: Baseline; 1-day post dose; 1-week post dose; 2-week post dose; 3-week post-dose; 4-week post-dose; week 10; week 14; week 18; week 22; week 26.

  11. Stanford Expectations of Treatment Scale (SETS)

    Used to assess participants' positive and negative treatment expectancies. Rated on a 7-item Likert scale, with minimum score of 6, and maximum score of 42. Higher scores generally indicate greater expectations for positive expectancy scores and greater concerns for negative expectancy scores.

    Time frame: Baseline

  12. Working Alliance Inventory (WAI)

    Used to assess the participants' therapeutic relationship with their therapists. Scores range from 12 to 60 with higher scores indicating stronger therapeutic alliance.

    Time frame: Week 2 (visit 3); 1-day post dose; 1-week post dose.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 24 months is below that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 12, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Jun 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Centre for Addiction and Mental Health is now Recruiting
Oct 26, 2026
Secondary outcomes
5 description edited
What changed in the outcomes
  • Description5 Dimensional Altered States of Consciousness (5-DASC): how it is measured was reworded
  • DescriptionChallenging Experience Questionnaire (CEQ): how it is measured was reworded
  • DescriptionMystical Experience Questionnaire (MEQ): how it is measured was reworded
  • DescriptionPsychological Insight Questionnaire (PIQ): how it is measured was reworded
  • DescriptionStanford Expectations of Treatment Scale (SETS): how it is measured was reworded
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    Centre for Addiction and Mental Health is now Recruiting
    Secondary outcomes 5 description edited
    What changed in the outcomes
    • Description5 Dimensional Altered States of Consciousness (5-DASC): how it is measured was reworded
    • DescriptionChallenging Experience Questionnaire (CEQ): how it is measured was reworded
    • DescriptionMystical Experience Questionnaire (MEQ): how it is measured was reworded
    • DescriptionPsychological Insight Questionnaire (PIQ): how it is measured was reworded
    • DescriptionStanford Expectations of Treatment Scale (SETS): how it is measured was reworded
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07405606
Responsible party
Bernard Le Foll (Principal Investigator, Centre for Addiction and Mental Health) — Principal investigator
First posted
Feb 12, 2026
Start date
Mar 23, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Bernard Le Foll
Contact
bernard.lefoll@camh.ca
+14165358501 ext. 33111
Esther Kim
Contact
esther.kim@camh.ca
+14165358501 ext. 32848

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion